WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock

Open Broker Account
$234.40+14.15 (+6.42%)
Updated Dec 2, 2022
ALNY Price
$234.40
Fair Value Price
$241.32
Market Cap
$28.84B
52 Week Low
$117.58
52 Week High
$236.80
P/E
-23.99x
P/B
-426.36x
P/S
25.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$960.92M
Earnings
-$1.18B
Gross Margin
83.8%
Operating Margin
-105.88%
Profit Margin
-123%
Debt to Equity
-53.27
Operating Cash Flow
-$559M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ALNY Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALNY ($234.40) is undervalued by 2.87% relative to our estimate of its Fair Value price of $241.32 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALNY ($234.40) is not significantly undervalued (2.87%) relative to our estimate of its Fair Value price of $241.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALNY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALNY due diligence checks available for Premium users.

Be the first to know about important ALNY news, forecast changes, insider trades & much more!

ALNY News

Valuation

ALNY fair value

Fair Value of ALNY stock based on Discounted Cash Flow (DCF)
Price
$234.40
Fair Value
$241.32
Undervalued by
2.87%
ALNY ($234.40) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALNY ($234.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALNY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALNY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-23.99x
Industry
13.84x
Market
21.89x

ALNY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-426.36x
Industry
5.06x

ALNY's financial health

Profit margin

Revenue
$264.3M
Net Income
-$405.9M
Profit Margin
-153.6%
ALNY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALNY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.5B
Liabilities
$3.6B
Debt to equity
-53.27
ALNY's short-term assets ($2.69B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALNY's long-term liabilities ($2.83B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALNY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$115.3M
Investing
$313.9M
Financing
$297.0M
ALNY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALNY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALNY$28.84B+6.42%-23.99x-426.36x
GMAB$30.98B+1.44%41.14x8.79x
RPRX$26.63B-0.43%38.46x2.56x
SGEN$22.73B+1.15%-35.48x8.05x
ARGX$22.15B+0.77%-22.89x7.38x

Alnylam Pharmaceuticals Stock FAQ

What is Alnylam Pharmaceuticals's quote symbol?

NASDAQ: ALNY) Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol ALNY. Alnylam Pharmaceuticals stock quotes can also be displayed as NASDAQ: ALNY.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

What is the 52 week high and low for Alnylam Pharmaceuticals (NASDAQ: ALNY)?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's 52-week high was $236.80, and its 52-week low was $117.58. It is currently -1.01% from its 52-week high and 99.35% from its 52-week low.

How much is Alnylam Pharmaceuticals stock worth today?

(NASDAQ: ALNY) Alnylam Pharmaceuticals currently has 123,028,234 outstanding shares. With Alnylam Pharmaceuticals stock trading at $234.40 per share, the total value of Alnylam Pharmaceuticals stock (market capitalization) is $28.84B.

Alnylam Pharmaceuticals stock was originally listed at a price of $7.00 in Jun 1, 2004. If you had invested in Alnylam Pharmaceuticals stock at $7.00, your return over the last 18 years would have been 3,248.57%, for an annualized return of 21.54% (not including any dividends or dividend reinvestments).

How much is Alnylam Pharmaceuticals's stock price per share?

(NASDAQ: ALNY) Alnylam Pharmaceuticals stock price per share is $234.40 today (as of Dec 2, 2022).

What is Alnylam Pharmaceuticals's Market Cap?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's market cap is $28.84B, as of Dec 5, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alnylam Pharmaceuticals's market cap is calculated by multiplying ALNY's current stock price of $234.40 by ALNY's total outstanding shares of 123,028,234.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.